Awarded contract

Manufacture of Lateral Flow Antigen tests for Sars-Covid-2

  • Department of Health and Social Care

F03: Contract award notice

Notice reference: 2021/S 000-005133

Published 14 March 2021, 9:08pm

Section one: Contracting authority

one.1) Name and addresses

Department of Health and Social Care

39 Victoria Street





United Kingdom

NUTS code

UKI32 - Westminster

Internet address(es)

Main address

Buyer's address

one.4) Type of the contracting authority

Ministry or any other national or federal authority

one.5) Main activity


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Manufacture of Lateral Flow Antigen tests for Sars-Covid-2

two.1.2) Main CPV code

  • 33141625 - Diagnostic kits

two.1.3) Type of contract


two.1.4) Short description

Manufacture of Lateral Flow Antigen tests for Sars-Covid-2 to respond to the urgent and growing need for more testing for the UK

two.1.6) Information about lots

This contract is divided into lots: No

two.1.7) Total value of the procurement (excluding VAT)

Lowest offer: £50,000,000 / Highest offer: £374,000,000 taken into consideration

two.2) Description

two.2.3) Place of performance

NUTS codes

two.2.4) Description of the procurement

Manufacture of Lateral Flow Antigen tests for Sars-Covid-2 to respond to the urgent and growing need for more testing for the UK

two.2.5) Award criteria


two.2.11) Information about options

Options: No

two.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

  • Extreme urgency brought about by events unforeseeable for the contracting authority


The Value of Contract (inc. any possible extensions, exc. VAT) stated in this Contract Award Notice is not a committed value for the contract. Volumes supplied via this contract are forecast quarterly. The stated Value of Contract (inc. any possible extensions, exc. VAT) is an estimate based on projected volumes in the event that all potential contract extensions are enacted.1. The COVID-19 outbreak is a Public Health Emergency of International Concern as declared by the World Health Organisation on 30 January 2020. The WHO Director General characterised COVID-19 as a pandemic on 11 March 2020.2. A key element of ensuring an effective response to the pandemic is ensuring that there is adequate testing. Therefore, ensuring surge LFT capacity, including sufficient availability of Lateral Flow Tests, is critical. 3. Mass testing of the UK Population is a key step in bringing the Pandemic under control. (Lateral Flow Tests produce quicker results than the current PCR (Polymerase Chain Reaction) test, and do not require a lab processing step.) LFT tests have only recently become viable as a means of testing, with multiple tests being progressed through to certification and approval. This was unforeseen by the DHSC and outside its control.4. DHSC's market analysis data demonstrates that the global market for LFT is volatile and highly competitive. Global manufacturing capability is limited to circa 120m units per day. World demand often outstrips supply. DHSC requirement is driven by the progress of the pandemic (including emerging variants), the changing efficacy of available LTF products and the severity of the second wave. That requirement means that the UK must make substantial purchases of tests.5. DHSC has been tasked with ensuring security of supply of a critical consumable asset (Lateral Flow Antigen tests) in a volatile and competitive global market place. This demand contract pursues that mandate by guaranteeing that DHSC is able to receive a stable supply of completed lateral flow test devices manufactured by a diagnostics tests manufacturing specialist, within the urgent timeframes required by the project. 6.A market engagement exercise for DHSC was carried out at pace due to the urgent requirement. Omega Diagnostics were identified via this process. 7. DHSC is satisfied the tests permitting use of the Negotiated procedure without prior publication (Regulation 32(2)(c)) are met:A. As far as is strictly necessary: The surge LFT capacity was identified as strictly necessary to meet the demand to scale up the testing programme in the UK.B. There are genuine reasons for extreme urgency: It is responding to COVID-19 immediately because of public health risks presenting a genuine emergency.C. The events that have led to the need for extreme urgency were unforeseeable: The Commission itself confirmed: “The current coronavirus crisis presents an extreme and unforeseeable urgency – precisely for such a situation our European rules enable public buyers to buy within a matter of days, even hours, if necessary.” (Commissioner Breton, Internal Market, 01.04.2020).D. It is impossible to comply with the usual timescales in the PCR: It is not possible to comply with the timescales of another procedure due to the urgent requirement to ensure effective capacity.E. The situation is not attributable to the contracting authority – DHSC has not done anything to cause or contribute to the need for extreme urgency.

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section five. Award of contract

A contract/lot is awarded: Yes

five.2) Award of contract

five.2.1) Date of conclusion of the contract

12 February 2021

five.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

five.2.3) Name and address of the contractor


Omega House, Hillfoots Business Village, Alva


FK12 5DQ


United Kingdom

NUTS code
National registration number


The contractor is an SME


five.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £374,000,000

Total value of the contract/lot: £374,000,000

Section six. Complementary information

six.4) Procedures for review

six.4.1) Review body

The High Court






United Kingdom

Internet address